RESULTS	Median OS was > 13 months in all treatment groups ; nevertheless , OS was not significantly increased with bevacizumab [ HR ( 95 % CI ) 0.93 ( 0.78-1 .11 ) , P = 0.420 and 1.03 ( 0.86-1 .23 ) , P = 0.761 ] for the 7.5 and 15 mg/kg groups , respectively , versus placebo .\